Press Releases

06 March 2023

Success-driven hit discovery enabled by success in the synthesis

San Francisco, USA, and Kyiv, Ukraine, March 6 2023. OpenBench, the first success-driven service for small molecule hit discovery, and Enamine, the world’s leading provider of astronomical numbers of compounds for biological screening, today announced the extension of their collaboration to enrich global early discovery efforts.

15 December 2022

Pharmacelera to partner with Enamine for the screening of ultra-large chemical libraries

Barcelona, Spain, and Kyiv, Ukraine, 15 December 2022. Pharmacelera, the leading provider of computational tools for hit discovery, and Enamine, the developer of REAL Database – the world’s largest virtual library of highly feasible compounds, have announced a partnership to jointly provide an efficient solution for hit finding. Ultra-large chemical libraries are observed as one of the key paradigms to access an unexplored chemical space. How to traverse these enormous spaces accurately is a research area that has raised the interest of the pharmaceutical industry, since finding novel hits with chemical diversity is a fundamental pillar in drug discovery.

18 October 2021

Enamine brings Levin “nitrogen-deleting” reagent to the market

Kyiv, Ukraine, 18 October 2021. Several months ago, Prof. Levin and co-workers from University of Chicago developed an elegant method for the “skeletal editing” of organic molecules by nitrogen atom deletion (see Nature 2021, 593, 223–227). Their strategy included the use of an anomeric N-pivaloyloxy-N-alkoxyamide amide as the key reagent. Enamine, the world-leading compound supplier, is proud to announce that this reagent has been just added to the company’s product catalog. The compound is now available from the company’s stock in multigram quantities.

Iryna Iavniuk, Business Development Director at Enamine, explains: “We at Enamine always look for the most recent scientific findings in all areas of chemistry and use them to expand and improve our products immediately. We were happy to collaborate with Mark Levin on the commercialization of his fascinating reagent – a remarkable addition to our reagent collection.”

Prof. Dr. Oleksandr Grygorenko, Consulting Scientist at Enamine, adds: “I was really excited when I saw Prof. Levin’s Nature publication on the nitrogen deletion method while surfing the literature. When Mark contacted us, we readily agreed to collaborate. Our chemists quickly reproduced his published protocols, performed scale-up to 50 g of the reagent, demonstrated its applicability, and checked the storage stability. Now, the compound is available from EnamineStore:

Prof. Dr. Mark Levin, Assistant Professor at University of Chicago, comments: “Hopefully anyone who wants to give our methods a whirl will be able to take advantage of this wonderful offering from Enamine. I am looking forward to all the creative applications of nitrogen deletion that this will enable!”

Conflict of interest statement: Hereby the parties confirm that Prof. Levin or his group has no financial interest in commercialization of EN300-33050767. No specialized data was transferred to Enamine apart from that already published in the literature.

Download pdf

24 June 2021

Enamine selects Chemspace to advance its catalog business

Kyiv, Ukraine, June 24, 2021. Enamine Ltd. a provider of drug discovery services empowered with the world’s largest collections of building blocks, fragments, and screening compounds announced today that it forms a strategic alliance with Chemspace, an online marketplace leader for small molecules, and will use the company as its exclusive aggregator platform to supply worldwide all its catalogue products starting from January 1, 2022. Chemspace will be the only online commercial resource in the world that will enable accessing and searching all Enamine’s catalogs. Enamine will continue direct supplies to the drug discovery community and at the same time will cease its historical collaborations with all other compound aggregator platforms.

Read press release

24 February 2021

Enamine extend collaboration with prominent Swiss Biotech

A new multi-year drug discovery agreement will focus on CNS drug discovery

Kyiv, Ukraine, February 24 2021 - Enamine Ltd. a provider of drug discovery services empowered with the world’s largest collections of building blocks, fragments and screening compounds announced today that it has extended its long-standing research collaboration with Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company specialized in allosteric modulation-based drug discovery and development. Enamine is providing Addex with its integrated capability in medicinal chemistry, pharmacology and ADME/PK (Absorption, Distribution, Metabolism, Excretion/Pharmacokinetics) to efficiently support Addex’ small molecule CNS drug discovery programs.

Read press release

17 September 2020

Enamine Ltd. Released Coronavirus Library to Support COVID-19 Research Programs

Enamine Ltd., a leading chemical research organization and producer of the world’s largest collections of novel building blocks (225,000+) and screening compound libraries (2,740,000+), today announced the release of the Coronavirus Library. The new screening library capitalizes on Enamine’s decades of chemical R&D, advanced library design expertise, and experience with creating focused antiviral libraries. Enamine is a participant of a global Open Science initiative “COVID Moonshot”, aimed at discovering novel therapeutics against SARS-CoV-2.

Read press release

11 March 2020

Enamine to be the exclusive supplier of Astex’ MiniFrag Library

Enamine Ltd. and Astex Pharmaceuticals (UK) have cooperated to provide wide access to Astex’ MiniFrag library, an efficient Fragment-based Drug Discovery tool for identification of hot and warm spots of protein targets. The Library is readily available from Enamine in any suitable format, including dry samples or assay-ready high concentration (1M, 100mM) aqueous soaks in containers of preferred type. The detected MiniFrag hits can be followed-up with a wide range of stock available and synthetically feasible derivatives as well as with building blocks for introduction of the relevant structural features for lead optimization.

Read press release

05 November 2019

Cyclica Collaborates With Enamine to Use REAL Technology in Its Ligand Design Platform for AI-augmented Drug Design

Cyclica, Inc. announced a collaboration with Enamine Ltd. to explore its huge readily accessible chemical space using Cyclica’s state-of-the-art AI-driven Ligand Design™ platform. The companies aim to empower Cyclica’s patented, evolutionary algorithm with new design options based on the 73,000 Enamine’s in-stock building blocks and 171 thoroughly validated synthesis procedures. The joint effort is expected to enable Cyclica’s Ligand Design™ to identify novel molecules with desired polypharmacological properties out of over 11 billion REAL™ (readily accessible) compounds. At least 80% of these compounds will be synthesized by Enamine within only 3-4 weeks.

Read press release

26 March 2019

Enamine extends multi-year drug discovery collaboration with Lundbeck

Enamine and H. Lundbeck A/S (Lundbeck) announced the expansion of their research collaboration. Enamine will support Lundbeck’s in-house discovery chemistry competencies with three principal assets enabling Lundbeck to optimally identify and develop hit series in its multiple research programs. A large diverse library of 100 000 new screening compounds was done for hit finding activities on numerous therapeutic targets. Enamine’s make-on-demand REAL compounds are for efficient access to billions of novel chemical compounds. Enamine FTE increased dedicated team of chemists to effectively support Lundbeck on all hit related follow-up activities backed by immediate access to over 170 000 building blocks in Enamine’s inventory.

Read press release

19 June 2018

Enamine and TBD Biodiscovery collaborate to provide GMP-based services

Enamine and TBD Biodiscovery have entered into a collaboration agreement. The partnership aims to manage the transition of chemical synthesis of novel intermediates from laboratory to bulk scale under GMP standards utilizing Enamine’s know-how and process development expertise. This will help researchers meet the manufacturing feasibility criteria required for drug candidate selection, providing a rapid and cost effective scaled supply of new compounds.
Read press release

15 March 2018

Enamine collaborates with ChemAxon to create a convenient web-based search in immense chemical space

Enamine and ChemAxon today announced the launch of jointly-created online resource (available at to allow researchers worldwide to explore the chemical space of REAL database. The resource is aimed to provide the drug discovery community with the efficient solutions in hit-to-lead development. The querying of the chemical space is empowered by ChemAxon’s proprietary fast similarity search tool – MadFast, delivering sub-second response against hundreds of millions of molecules.
Read press release

25 January 2018

Enamine expands collaboration with UCSF

Enamine Ltd. has today announced that it has expanded its collaboration on ZINC, a comprehensive online database of purchasable compounds curated by the Irwin and Shoichet laboratories in the Department of Pharmaceutical Chemistry at the University of California, San Francisco (UCSF). Via ZINC, Enamine will provide researchers at UCSF and the global drug-discovery community with access to the company’s REAL database, a unique database of more than 300 million novel synthetically feasible chemical structures as an efficient source of potential new compounds for a breadth of drug discovery projects.
Read press release

01 August 2017

Axxam enters into a Research Collaboration with Enamine

Axxam S.p.A. and Enamine Ltd. announced the start of a Research Collaboration to enhance the Axxam small molecule screening library with the addition of a further set of compounds aimed at early-stage CNS drug discovery, achieving a total library size of ca. 280 000 compounds.
Read press release

06 June 2012

Enamine creates the alliance to discover novel Rhomboid Protease inhibitors as potential drugs

A collaboration agreement has been signed between Enamine, the Medical Research Council Laboratory of Molecular Biology (MRC LMB), Cambridge, UK, and the Institute of Organic Chemistry and Biochemistry of the Academy of Sciences of the Czech Republic (IOCB), Prague, Czech Republic. The new alliance is aimed at discovering novel Rhomboid Protease inhibitors as potential drugs to treat infectious, parasitic, oncological, immune and cardiovascular diseases. Enamine will provide the MRC LMB and IOCB with access to its integrated drug discovery capabilities, including Molecular Modeling, Compound Library, Screening Assays, Hit Finding and Characterization, Hit to Lead Chemistry and ADMET. The three parties will seek to partner the small molecule inhibitors generated with pharmaceutical companies for onward clinical development. The collaboration agreement was negotiated by MRC Technology on behalf of MRC LMB.
Read press release

16 January 2023

Enamine and UORSY collaborate on creating Legacy Screening Collection

Kyiv, Ukraine, January 16, 2023. Enamine Ltd., the world’s leading designer and supplier of screening compound libraries and building blocks, together with UORSY, a top Ukrainian chemical company producing products for early drug discovery, announced today the creation of a joint “Legacy” screening collection.

22 November 2021

Enamine makes HFIPS reagent more accessible

Kyiv, Ukraine, 22 November 2021. Recently, Prof. Magolan and coworkers from McMaster University (Hamilton, Ontario, Canada) reported that hexafluoroisopropyl sulfamate (HFIPS) is a convenient reagent for the sulfamoylation of alcohols and amines (Org. Lett. 2021, 23, 3373–3378). HFIPS has also been used for metal-catalyzed C–H aminations (J. Am. Chem. Soc. 2014, 136, 5783–5789) and for the synthesis of aziridines using silver catalysis (Synthesis 2018, 50, 4462–4470) or electrochemical conditions (Angew. Chem. Int. Ed. 2018, 57, 5695–5698). Enamine has adapted and scaled-up the published procedure to synthesize HFIPS and make it more accessible to scientists worldwide. The reagent is now available in Enamine’s catalogue in multigram quantities.

Iryna Iavniuk, Business Development Director at Enamine, comments: “We at Enamine are committed to making novel reagents immediately accessible to our customers. We have successfully applied the HFIPS reagent in one of our projects previously and were happy to produce it for commercialization.”

Prof. Dr. Oleksandr Grygorenko, Consulting Scientist at Enamine, explains: “Dr. Jarrod Johnson, a Research Associate in the Magolan group, contacted us to point out that there was a supply gap with HFIPS. We recognized the usefulness of the reagent and happily agreed to begin commercialization. Our chemists quickly reproduced the published procedure to synthesize 50 grams of the reagent and HFIPS is now available from EnamineStore:”

Dr. Jarrod Johnson from McMaster University, adds: “We like the ease and simplicity of using HFIPS for sulfamoylation chemistry and hope it might become the go-to reagent for medicinal chemists making sulfamates and sulfamides.”

Prof. Dr. Jakob Magolan from McMaster University, comments: “It’s great to see Enamine now offering bulk HFIPS. I expect that this will enable creative scientists around the world to further extend the scope and applicability of this useful little reagent.”

Conflict of interest statement: Hereby the parties confirm that Prof. Magolan and his group have no financial interest in commercialization of EN300-1987789. No specialized data was transferred to Enamine apart from that already published in the literature.

Download pdf

10 June 2021

Enamine implements CDD Vault to digitalize its integrated medicinal chemistry, ADME-PK and screening services

The company's expansion in the biological assay space aided by the data platform

SAN FRANCISCO and KYIV, Ukraine, June 10, 2021 - Enamine, a leading provider of R&D Services as well as Screening Compounds, Fragments, Building Blocks and specialized libraries for Drug Discovery, announced today that it had implemented Collaborative Drug Discovery's CDD Vault to manage its biological assay data. The platform will enable seamless and secure exchange of information between Enamine and its partners in pharmaceuticals, biotechs and other organizations conducting drug discovery research.

Read press release

24 September 2020

Enamine is selected for Horizon 2020 global project “AIDD” - Advanced Machine Learning for Innovative Drug Discovery" to boost Artificial Intelligence (AI) for chemistry and drug discovery

Enamine Ltd., a leading chemical research organization and producer of the world’s largest collections of novel building blocks (225,000+) and screening compound libraries (2,740,000+), has joined the Advanced Machine Learning for Innovative Drug Discovery (AIDD) program, funded by the European Union within the framework of the Marie-Skłodowska-Curie Actions (MSCA) with a budget of Euros 3.93 million. The project, coordinated by Helmholtz Zentrum München,Germany, brings together fifteen institutions from eleven countries in addition to the University of British Columbia (Canada) to train sixteen PhD students in close collaboration with associated partners from the USA, Australia, China, Israel and other countries and develop next generation AI and Machine Learning (ML) models and systems for drug discovery.

Read press release

19 November 2019

Optibrium collaborates with Enamine and BioSolveIT to add REAL Space Search Tool to StarDrop

Optibrium™, BioSolveIT™ and Enamine™ today announce a three-way collaboration enabling efficient search of Enamine’s REAL Space directly from within Optibrium’s StarDrop™ software. This extension to StarDrop is powered by BioSolveIT’s proprietary Feature Trees (FTrees) technology, to search a gigantic chemical space of over 11 billion readily accessible compounds and identify novel compounds that are similar to a query structure of interest. The resulting chemical structures and data are pre-formatted and ready to evaluate using StarDrop’s comprehensive suite of integrated software for small molecule design, optimisation and data analysis.

Read press release

04 September 2018

Optibrium and Enamine collaboration extends commercial compound database access for StarDrop users

Optibrium™ today announced a collaboration with Enamine. The collaboration provides StarDrop™ users with easy access to EnamineStore, a database of their commercially available screening compounds and chemical building blocks. StarDrop has been developed to connect seamlessly with a wide variety of internal and external informatics systems and this latest partnership further extends the wealth of information available to users through StarDrop and its capabilities for small molecule design, optimisation and data analysis in drug discovery.

StarDrop provides free access to the Enamine database to easily search for commercially available compounds and building blocks. Enamine has over 3.3 million screening compounds and a further library of 7.8 million building blocks available to order from EnamineStore. The link enables users not only to search for specific compounds, but also find those that are structurally similar to their most interesting hits and leads or contain relevant substructures. This provides an invaluable tool for researchers to quickly enrich the understanding of their chemical structure-activity relationships.
Read press release

04 June 2018

New REAL Space Navigator Breaks Billion Compound Barrier

Enamine Ltd., a leading compound supplier and BioSolveIT GmbH, a premium provider of drug discovery software, today announced the availability of the next generation of REAL Space Navigator, an efficient search tool within the world’s largest purchasable chemical space. Originally launched in February this year, Version 2 of REAL Space Navigator now offers ‘search and find’ access to an incredible 3.8 billion small molecular weight compounds ready for purchase.
Read press release

08 February 2018

Enamine and BioSolveIT Launch the World's Largest Searchable Chemical Space for Novel Compound Sourcing

Enamine and BioSolveIT today announced the launch of the ‘REAL Space Navigator’. Jointly developed, the new software tool capitalizes on Enamine’s REAL (readily accessible) virtual compound concept and provides efficient ‘search & find’ access to more than 640 million pharma-oriented molecules, to date the world's largest chemical space of commercially accessible compounds.
Read press release

10 January 2018

Enamine supplies DSI poised fragment and analogue libraries to Diamond Light Source XChem facility and SGC Oxford screening efforts

Diamond Light Source (Diamond) and the Structural Genomic Consortium (SGC) Oxford announced today that Enamine will become a key supplier of poised fragment and analogue libraries to its XChem facility. Enamine will offer a new generation of the hit-finding library, Diamond-SGC-iNEXT (DSI) Poised Library to enable fast and productive fragment-based lead discovery (FBLD).
Read press release

18 April 2012

Collaboration agreement has been signed with UORSY

Enamine and UkrOrgSynthesis Ltd (UORSY), a leading Ukrainian supplier of chemical building blocks and compounds for high-throughput screening, announced they have signed a collaboration agreement to offer chemical building blocks to the drug discovery industry cooperatively. By combining their catalogues, the companies become the largest global manufacturer and seller of building blocks, with 60 000 products available from stock for immediate delivery and an array of ca. 8 million tangible building blocks deliverable with synthetic success rate of 80%.
Read press release

24 January 2011

Molplex and Enamine announced a new partnership

Molplex and Enamine announced a new partnership to offer Enamine's screening compounds through the Molplex on-line drug design and assay ready chemical supply services. The agreement is a major step towards eliminating the high start-up costs of drug discovery, bringing sophisticated drug design, compound management and assay ready chemistry to the world's drug discovery scientists on demand. The agreement adds Molplex online drug design systems to the deep experience in organic chemistry and compound management of Enamine to solve the problem of generating viable chemical leads for novel targets.
Read press release